In a patient with hepatocellular carcinoma and metastatic disease whose peripheral blood smear shows a chronic myelogenous leukemia pattern and who presents with green‑colored stool followed by melena and fresh rectal bleeding, what are the differential diagnoses and recommended management?

Management of Green Stools, Melena, and Rectal Bleeding in Hepatocellular Carcinoma with CML Pattern

This patient requires immediate resuscitation with concurrent upper endoscopy to exclude an upper GI source, followed by urgent colonoscopy if the upper tract is clear, while simultaneously investigating the CML pattern as it may represent a paraneoplastic leukemoid reaction from HCC rather than true leukemia.

Immediate Assessment and Resuscitation

The progression from green stools to melena to fresh rectal bleeding suggests evolving gastrointestinal hemorrhage requiring urgent intervention. Resuscitation must occur concurrently with diagnostic evaluation 1.

Critical Initial Steps:

• Calculate shock index (heart rate ÷ systolic BP): if >1, the patient is unstable and requires aggressive resuscitation 2
• Correct coagulopathy: INR >1.5 requires fresh frozen plasma and vitamin K; platelets if <50,000/µL 1
• In cirrhotic patients with HCC, coagulopathy correction is essential before any endoscopic intervention 1
• Establish large-bore IV access and begin blood product transfusion based on hemodynamic status

Differential Diagnosis

Primary Bleeding Sources:

Upper GI sources (must exclude first):

• HCC with gastroduodenal invasion or fistula formation
• Portal hypertensive gastropathy from underlying cirrhosis
• Tumor erosion into upper GI tract

Lower GI sources:

1. HCC metastasis to colon (rare but documented): Can present as submucosal tumor with ulceration causing hematochezia 3, 4, 5. Occurs via hematogenous spread or direct invasion 6
2. Tumor hemorrhage from metastatic disease: Chemotherapy-induced tumor necrosis can cause bleeding 7
3. Thrombocytopenia-related bleeding: CML pattern may indicate bone marrow involvement causing platelet dysfunction 7
4. Angiodysplasia or diverticular bleeding: Common in older patients with liver disease 1

The CML Pattern:

Critical distinction required:

• Paraneoplastic leukemoid reaction from HCC (more likely): Growth factor-driven neutrophilic reaction that mimics CML 8. Check neutrophil alkaline phosphatase (elevated in leukemoid reaction, low in true CML)
• True CML: Requires BCR-ABL testing to confirm
• Bone marrow infiltration by HCC: Rare but possible

The green stools likely represent rapid GI transit with bile pigment, followed by melena indicating upper GI bleeding, then fresh blood suggesting lower GI source or massive upper GI hemorrhage.

Diagnostic Algorithm

Step 1: Localize the Bleeding Source

First-line: Upper endoscopy (EGD) 1, 9

• Approximately 10-15% of presumed lower GI bleeds originate from upper tract
• Must be performed urgently in unstable patients
• If positive: treat endoscopically

If EGD negative and patient unstable with ongoing bleeding:

• CT angiography if bleeding rate >0.5 mL/min 2
• Catheter angiography with embolization for active bleeding 1, 2

If EGD negative and patient stable:

• Colonoscopy (urgent or within 24 hours) 1, 2
• Look specifically for submucosal masses with ulceration (HCC metastasis) 4
• Biopsy any suspicious lesions for immunohistochemistry: Hepatocyte+, CK20-, CDX2-, Villin- confirms HCC metastasis 3

Step 2: Investigate the CML Pattern

Immediate tests:

• Neutrophil alkaline phosphatase score (elevated suggests leukemoid reaction, not true CML) 8
• BCR-ABL by PCR (negative excludes CML)
• Peripheral smear review: look for left shift vs. full spectrum of myeloid cells
• Bone marrow biopsy only if diagnosis remains unclear

Treatment Strategy

For Active Bleeding:

Endoscopic management:

• Combination therapy: injection + mechanical (clips) or ablative therapy (argon plasma coagulation) 10
• Caution: In thrombocytopenic patients, ensure platelet support available even if count >50,000/µL due to chemotherapy-induced platelet dysfunction 7
• Biopsy in thrombocytopenic/cirrhotic patients carries high perforation risk 7

If endoscopy fails or bleeding site not identified:

• Angiographic embolization for ongoing hemorrhage 1, 2
• Surgery as last resort in hemodynamically unstable patients 1

For HCC Colonic Metastasis (if identified):

Surgical resection is the treatment of choice for isolated colonic metastasis causing bleeding 3, 4, 5:

• Right hemicolectomy for ascending colon/hepatic flexure lesions
• Partial colectomy for other locations
• Provides local control and prevents recurrent life-threatening hemorrhage
• Median survival post-resection: 2-3 years in selected cases 3

Alternative if surgery contraindicated:

• Angiographic embolization 10
• External beam radiotherapy for palliation 10
• Endoscopic hemostasis (temporary measure) 10

For Underlying HCC with Metastatic Disease:

Given metastatic disease, systemic therapy options include 11, 12:

• Combination immunotherapy (atezolizumab + bevacizumab) if liver function preserved
• Sorafenib or lenvatinib as alternatives
• However, active bleeding is a contraindication to bevacizumab due to hemorrhage risk 7

For Leukemoid Reaction:

If confirmed as paraneoplastic phenomenon 8:

• No specific treatment for leukocytosis itself
• Treat underlying HCC
• Monitor for complications (hyperviscosity, though rare)
• Leukemoid reaction typically resolves with tumor control

Critical Pitfalls to Avoid

1. Do not assume lower GI bleeding without excluding upper source - 10-15% of hematochezia originates above ligament of Treitz 1, 9

2. Do not perform colonoscopy in neutropenic patients if CML represents true leukemia with neutropenia - extremely high perforation risk 7

3. Do not biopsy aggressively in thrombocytopenic/cirrhotic patients - even "adequate" platelet counts may have dysfunction 7

4. Do not start bevacizumab-based therapy until bleeding controlled - causes ulceration, perforation, and poor wound healing 7

5. Do not delay surgical consultation in patients with persistent bleeding despite endoscopic/radiologic intervention 1

6. Do not assume CML without BCR-ABL testing - HCC commonly causes leukemoid reactions that mimic CML 8

Prognosis

The combination of metastatic HCC with GI bleeding carries poor prognosis. However, local control of bleeding source is essential for quality of life and may extend survival by months to years in selected patients 3, 5. The leukemoid reaction itself, if paraneoplastic, indicates advanced disease but does not independently worsen prognosis beyond the underlying HCC stage 8.